Finding new antifungal compounds to fight resistant infections
Official title: A Platform to Identify Antifungal Compounds with Novel Action Mechanisms
Funded at Intact Genomics, INC. · NIH-10760421 · Data updated 2026-11-12
This study is looking for new medicines to fight stubborn fungal infections that don't respond well to current treatments, and it's for anyone who might benefit from better options in the future.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Intact Genomics, INC. NIH-funded |
| Lab location | 1 site (St Louis, United States) |
| Project start | July 19, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $300,156 |
| NIH project number | 1R43AI179388-01 |
| Project ID | NIH-10760421 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from fungal infections that are resistant to existing antifungal medications.
✕Less likely to help
Patients with non-fungal infections or those who do not have resistant fungal infections may not benefit from this research.
What this research studies
This research focuses on discovering new antifungal compounds that can effectively combat fungal pathogens, which are increasingly resistant to current treatments. By utilizing advanced techniques in metagenomics and RNA sequencing, the researchers aim to explore the genetic makeup of filamentous fungi, specifically Aspergillus nidulans, to identify novel antifungal agents. The project combines innovative methodologies to screen for these compounds and assess their potential effectiveness against various fungal infections. Patients may benefit from new treatment options that could emerge from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antifungal treatments that are effective against resistant fungal infections.
How similar studies have gone: Other research has shown promise in discovering new antifungal agents through innovative screening methods, indicating that this approach has potential for success.
Where this research is happening
-
Intact Genomics, INC.
St Louis, United States Active
Researchers
- Principal investigator: Wu, Chengcang Charles — Intact Genomics, INC.
- Study coordinator: Wu, Chengcang Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.